Compare · MRNA vs TCON
MRNA vs TCON
Side-by-side comparison of Moderna Inc. (MRNA) and TRACON Pharmaceuticals Inc. (TCON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TCON operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $79.63B.
- MRNA has hit the wire 16 times in the past 4 weeks while TCON has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 1 for TCON).
- Company
- Moderna Inc.
- TRACON Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $79.63B
- -
- 1M return
- -18.79%
- -
- 1Y return
- +713.39%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2015
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 1
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
TRACON Pharmaceuticals Inc.
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Latest MRNA
- President Stephen Hoge exercised 152,905 shares at a strike of $12.21, sold $16,900,019 worth of shares (78,375 units at $215.63) as part of a pre-agreed trading plan and gifted 400,000 shares, decreasing direct ownership by 20% to 1,311,095 units (SEC Form 4)
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest TCON
- Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.
- SEC Form 15-12G filed by TRACON Pharmaceuticals Inc.
- SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.
- SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.
- SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.
- SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.
- SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.
- SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.
- SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.
- SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.